The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Classification of BRCA1 missense variants of unknown clinical significance


  • C M Phelan
  • V Dapic
  • B Tice
  • R Favis
  • E Kwan
  • F Barany
  • S Manoukian
  • P Radice
  • R B van der Luijt
  • B P M van Nesselrooij
  • G Chenevix-Trench
  • T Caldes
  • M de La Hoya
  • S Lindquist
  • S V Tavtigian
  • D Goldgar
  • Åke Borg
  • S A Narod
  • A N A Monteiro

Summary, in English

Background: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are responsible for a large proportion of breast - ovarian cancer families. Several missense variants have been identified throughout the gene but because of lack of information about their impact on the function of BRCA1, predictive testing is not always informative. Classification of missense variants into deleterious/ high risk or neutral/low clinical significance is essential to identify individuals at risk. Objective: To investigate a panel of missense variants. Methods and results: The panel was investigated in a comprehensive framework that included ( 1) a functional assay based on transcription activation; ( 2) segregation analysis and a method of using incomplete pedigree data to calculate the odds of causality; ( 3) a method based on interspecific sequence variation. It was shown that the transcriptional activation assay could be used as a test to characterise mutations in the carboxy-terminus region of BRCA1 encompassing residues 1396 - 1863. Thirteen missense variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, M1628V, T1685I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were specifically investigated. Conclusions: While individual classification schemes for BRCA1 alleles still present limitations, a combination of several methods provides a more powerful way of identifying variants that are causally linked to a high risk of breast and ovarian cancer. The framework presented here brings these variants nearer to clinical applicability.


  • Breastcancer-genetics

Publishing year







Journal of Medical Genetics





Document type

Journal article


BMJ Publishing Group


  • Medical Genetics




  • ISSN: 0022-2593